Tradewinds LLC. Takes $507,000 Position in Gilead Sciences, Inc. $GILD

Tradewinds LLC. acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 4,567 shares of the biopharmaceutical company’s stock, valued at approximately $507,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. GoalVest Advisory LLC grew its stake in shares of Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares in the last quarter. Corundum Trust Company INC bought a new position in Gilead Sciences in the 3rd quarter valued at about $26,000. Harbor Asset Planning Inc. acquired a new position in Gilead Sciences during the 2nd quarter valued at about $27,000. Putney Financial Group LLC increased its stake in Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 94 shares during the period. Finally, Howard Hughes Medical Institute bought a new stake in shares of Gilead Sciences during the 2nd quarter worth about $30,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Up 3.0%

Shares of GILD opened at $124.91 on Monday. The business’s 50-day moving average price is $123.36 and its 200 day moving average price is $118.11. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The stock has a market capitalization of $154.97 billion, a P/E ratio of 19.37, a P/E/G ratio of 0.66 and a beta of 0.33. Gilead Sciences, Inc. has a 1-year low of $91.68 and a 1-year high of $128.70.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. The company had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period last year, the company posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were issued a dividend of $0.79 per share. The ex-dividend date was Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s payout ratio is currently 48.99%.

Insider Activity

In related news, EVP Deborah H. Telman sold 53,646 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the completion of the sale, the executive vice president directly owned 43,676 shares in the company, valued at approximately $5,365,596.60. This trade represents a 55.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the transaction, the director owned 8,920 shares in the company, valued at approximately $1,115,713.60. This represents a 35.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 136,757 shares of company stock valued at $16,951,612 in the last ninety days. Corporate insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on GILD. Royal Bank Of Canada lowered their price objective on shares of Gilead Sciences from $105.00 to $100.00 and set a “sector perform” rating on the stock in a research note on Thursday, January 8th. Scotiabank started coverage on Gilead Sciences in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price target on the stock. BMO Capital Markets restated an “outperform” rating on shares of Gilead Sciences in a report on Tuesday, January 13th. UBS Group reaffirmed a “buy” rating on shares of Gilead Sciences in a report on Thursday. Finally, HSBC upped their price target on shares of Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a report on Wednesday, December 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $133.16.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.